View clinical trials related to Carcinoma Breast Stage IV.
Filter by:1st-line treatment of HER2/neu overexpressing breast cancer
The main objective of this study is to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and 3-weekly.